Business Context and Reporting Period
Mangoceuticals, Inc. (MGRX), a Texas corporation listed on the Nasdaq Capital Market, filed this Form 8-K on June 29, 2026. The report details a private placement transaction entered into on the same date.
Key Financial Metrics
The filing discloses a specific capital raise event but does not provide comprehensive financial statements, revenue, profit, cash flow, or debt metrics for the reporting period.
- Capital Raised: $272,000
- Shares Issued: 850,000 shares of restricted common stock
- Price Per Share: $0.32
- Investor Type: Accredited investor
Material Changes
The primary material change is the entry into a Material Definitive Agreement (Subscription Agreement) and the subsequent unregistered sale of equity securities. The company issued 850,000 shares to a single accredited investor. The filing text does not provide comparative financial data or prior period metrics to assess changes in revenue, margins, or liquidity.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, management commentary on future operations, or specific risk factors beyond standard regulatory disclosures. Key terms of the transaction include:
- Exemption: The sale was exempt from registration under Section 4(a)(2) and/or Rule 506 of Regulation D of the Securities Act of 1933.
- Restrictions: The securities are restricted and subject to transfer limitations; they may not be offered or sold absent registration or an exemption.
- Registration Rights: The agreement includes piggyback registration rights for a period of one year following the subscription date.
- Underwriting: No underwriters or agents were involved, and no underwriting discounts or commissions were paid.
Investor Verification Checklist
- Verify the full text of the Subscription Agreement (Exhibit 10.1) for additional covenants or conditions not summarized in the 8-K.
- Confirm the current total share count and dilution impact of the 850,000 newly issued shares.
- Review recent 10-Q or 10-K filings to assess the company's overall liquidity position relative to this $272,000 infusion.
- Check for any subsequent filings regarding the exercise of piggyback registration rights within the one-year window.